Safety Surveillance After Immunization With IXIARO

Status Completed

Clinical Trial Summary

This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese Encephalitis Vaccine IXIARO within the US Military, to detect adverse events that occur more frequently after IXIARO and to electronically follow up pregnancies during or shortly before which IXIARO was administered.

There will be no intervention and no individuals contacted.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01335412
Study type	Observational
Source	Valneva Austria GmbH
Contact
Status	Completed
Phase	N/A
Start date	March 2011
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03282370` - Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam	Phase 3
Recruiting	`NCT05568953` - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity	Phase 2
Completed	`NCT00776230` - Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling	Phase 3
Completed	`NCT00594958` - Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00595790` - Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00604708` - Immunogenicity Study of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00596271` - Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440	Phase 3
Not yet recruiting	`NCT01954810` - Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children	Phase 4
Completed	`NCT01246479` - Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study	Phase 3
Completed	`NCT00595270` - Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00605085` - Safety and Tolerability of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00314132` - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.	Phase 3
Completed	`NCT00596102` - Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51	Phase 3
Active, not recruiting	`NCT01981967` - Post-licensure Safety Study of IMOJEV® in Thailand	Phase 4
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT00314145` - A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX	Phase 3
Completed	`NCT00981630` - Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine	Phase 2
Completed	`NCT01656200` - A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2	Phase 4
Completed	`NCT01567865` - Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine	Phase 4
Unknown status	`NCT01163123` - Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan	N/A